Birdwatch Archive

Birdwatch Note

2023-03-14 14:55:43 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING

"Ivermectin has continually proved to be astonishingly safe for human use. Indeed, it is such a safe drug, with minimal side effects" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3043740/ Ivermectin is not only for parasites, it has some antiviral properties. Unbiased research before 2020 pandemic: https://portlandpress.com/biochemj/article/443/3/851/80615/Ivermectin-is-a-specific-inhibitor-of-importin https://www.pjps.pk/wp-content/uploads/pdfs/28/2/Paper-28.pdf https://pubmed.ncbi.nlm.nih.gov/22535622/ https://pubmed.ncbi.nlm.nih.gov/27242902/ https://www.nature.com/articles/ja201711 https://e-namtila.com/in-silico-binding-site-detection-of-ivermectin-with-influenza-a-virus-ns1-protein/

Written by C378931E048482D2BFDF00DC95644D6377CBCB812C79FF87D77B5E48595B3DA3
Participant Details

Original Tweet

Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1635623681522114564

Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.

All Information

  • ID - 1635655953637953540
  • noteId - 1635655953637953540
  • participantId -
  • noteAuthorParticipantId - C378931E048482D2BFDF00DC95644D6377CBCB812C79FF87D77B5E48595B3DA3 Participant Details
  • createdAtMillis - 1678805743022
  • tweetId - 1635623681522114564
  • classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
  • believable -
  • harmful -
  • validationDifficulty -
  • misleadingOther - 0
  • misleadingFactualError - 0
  • misleadingManipulatedMedia - 0
  • misleadingOutdatedInformation - 0
  • misleadingMissingImportantContext - 1
  • misleadingUnverifiedClaimAsFact - 0
  • misleadingSatire - 0
  • notMisleadingOther - 0
  • notMisleadingFactuallyCorrect - 0
  • notMisleadingOutdatedButNotWhenWritten - 0
  • notMisleadingClearlySatire - 0
  • notMisleadingPersonalOpinion - 0
  • trustworthySources - 1
  • summary
    • "Ivermectin has continually proved to be astonishingly safe for human use. Indeed, it is such a safe drug, with minimal side effects" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3043740/ Ivermectin is not only for parasites, it has some antiviral properties. Unbiased research before 2020 pandemic: https://portlandpress.com/biochemj/article/443/3/851/80615/Ivermectin-is-a-specific-inhibitor-of-importin https://www.pjps.pk/wp-content/uploads/pdfs/28/2/Paper-28.pdf https://pubmed.ncbi.nlm.nih.gov/22535622/ https://pubmed.ncbi.nlm.nih.gov/27242902/ https://www.nature.com/articles/ja201711 https://e-namtila.com/in-silico-binding-site-detection-of-ivermectin-with-influenza-a-virus-ns1-protein/

Note Status History

createdAt timestampMillisOfFirstNonNMRStatus firstNonNMRStatus timestampMillisOfCurrentStatus currentStatus timestampMillisOfLatestNonNMRStatus mostRecentNonNMRStatus participantId
2023-03-14 14:55:43 UTC
(1678805743022)
1969-12-31 23:59:59 UTC
(-1)
2023-03-15 05:09:59 UTC
(1678856999448)
NEEDS_MORE_RATINGS 1969-12-31 23:59:59 UTC
(-1)

Note Ratings

rated at rated by
2023-03-14 22:00:29 -0500 Rating Details
2023-03-14 20:04:00 -0500 Rating Details
2023-03-14 19:26:30 -0500 Rating Details
2023-03-14 17:40:35 -0500 Rating Details
2023-03-14 17:39:52 -0500 Rating Details
2023-03-14 17:05:23 -0500 Rating Details
2023-03-14 16:41:04 -0500 Rating Details
2023-03-14 16:19:45 -0500 Rating Details
2023-03-14 16:09:16 -0500 Rating Details
2023-03-14 15:48:59 -0500 Rating Details
2023-03-14 15:28:28 -0500 Rating Details
2023-03-14 13:25:05 -0500 Rating Details
2023-03-14 13:23:30 -0500 Rating Details
2023-03-14 13:00:09 -0500 Rating Details
2023-03-14 12:36:53 -0500 Rating Details
2023-03-14 12:28:01 -0500 Rating Details
2023-03-14 12:20:29 -0500 Rating Details
2023-03-14 12:08:20 -0500 Rating Details
2023-03-14 11:57:42 -0500 Rating Details
2023-03-14 11:44:57 -0500 Rating Details
2023-03-14 11:40:09 -0500 Rating Details
2023-03-14 11:28:46 -0500 Rating Details
2023-03-14 11:27:08 -0500 Rating Details
2023-03-14 11:17:09 -0500 Rating Details
2023-03-14 10:52:43 -0500 Rating Details
2023-03-14 10:52:24 -0500 Rating Details
2023-03-14 10:44:29 -0500 Rating Details
2023-03-14 10:44:00 -0500 Rating Details
2023-03-14 10:41:36 -0500 Rating Details
2023-03-14 10:35:49 -0500 Rating Details
2023-03-14 10:12:20 -0500 Rating Details
2023-03-15 13:34:13 -0500 Rating Details
2023-03-15 10:32:52 -0500 Rating Details
2023-03-15 05:55:23 -0500 Rating Details
2023-03-15 01:47:54 -0500 Rating Details
2023-03-15 00:20:56 -0500 Rating Details
2023-03-15 00:20:46 -0500 Rating Details
2023-03-14 22:42:56 -0500 Rating Details
2023-03-15 23:04:04 -0500 Rating Details
2023-03-14 16:09:16 -0500 Rating Details
2023-03-14 17:40:35 -0500 Rating Details
2023-03-15 01:47:54 -0500 Rating Details
2023-03-14 16:41:04 -0500 Rating Details
2023-03-15 23:04:04 -0500 Rating Details
2023-03-14 12:36:53 -0500 Rating Details
2023-03-14 20:04:00 -0500 Rating Details
2023-03-14 13:25:05 -0500 Rating Details
2023-03-14 12:28:01 -0500 Rating Details
2023-03-14 12:08:20 -0500 Rating Details
2023-03-15 00:20:56 -0500 Rating Details
2023-03-14 22:00:29 -0500 Rating Details
2023-03-14 13:23:30 -0500 Rating Details
2023-03-14 11:17:09 -0500 Rating Details
2023-03-15 10:32:52 -0500 Rating Details
2023-03-14 10:12:20 -0500 Rating Details
2023-03-15 00:20:46 -0500 Rating Details
2023-03-14 10:41:36 -0500 Rating Details
2023-03-14 11:27:08 -0500 Rating Details
2023-03-15 13:34:13 -0500 Rating Details
2023-03-14 19:26:30 -0500 Rating Details
2023-03-14 17:39:52 -0500 Rating Details
2023-03-14 15:48:59 -0500 Rating Details
2023-03-14 11:40:09 -0500 Rating Details
2023-03-14 13:00:09 -0500 Rating Details
2023-03-14 10:44:29 -0500 Rating Details
2023-03-15 05:55:23 -0500 Rating Details
2023-03-14 11:44:57 -0500 Rating Details
2023-03-14 10:52:43 -0500 Rating Details
2023-03-14 10:44:00 -0500 Rating Details
2023-03-14 22:42:56 -0500 Rating Details
2023-03-14 12:20:29 -0500 Rating Details
2023-03-14 15:28:28 -0500 Rating Details
2023-03-14 17:05:23 -0500 Rating Details
2023-03-14 10:52:24 -0500 Rating Details
2023-03-14 16:19:45 -0500 Rating Details
2023-03-14 11:28:46 -0500 Rating Details
2023-03-14 11:57:42 -0500 Rating Details
2023-03-14 10:35:49 -0500 Rating Details
2024-03-09 14:41:21 -0600 Rating Details